Items where Author is "Fulbright, H."
Hodgson, R. 
ORCID: 0000-0001-6962-2893, Walton, M. ORCID: 0000-0003-1932-3689, Fulbright, H. ORCID: 0000-0002-1073-1099 , Bojke, L. ORCID: 0000-0001-7921-9109, Walker, R. ORCID: 0000-0003-2765-7363, Llewellyn, A. ORCID: 0000-0003-4569-5136, Dias, S. ORCID: 0000-0002-2172-0221, Stewart, L. ORCID: 0000-0003-0287-4724, Steel, D. ORCID: 0000-0001-8734-3089, Lawrenson, J. ORCID: 0000-0002-2031-6390, Peto, T. ORCID: 0000-0001-6265-0381 & Simmonds, M. ORCID: 0000-0002-1999-8515 (2025).
A systematic review of the cost-effectiveness of anti-VEGF drugs for the treatment of diabetic retinopathy.
Health Technology Assessment,
doi: 10.3310/nhyk3694
Simmonds, M., Llewellyn, A., Walker, R. , Fulbright, H., Walton, M., Hodgson, R., Bojke, L., Stewart, L., Dias, S., Rush, T., Lawrenson, J. G. ORCID: 0000-0002-2031-6390, Peto, T. & Steel, D. (2024).
Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis.
Health Technology Assessment,
pp. 1-71.
doi: 10.3310/pcgv5709
Walton, M., Bojke, L., Simmonds, M. , Walker, R., Llewellyn, A., Fulbright, H., Dias, S., Stewart, L. A., Rush, T., Steel, D. H., Lawrenson, J. G. ORCID: 0000-0002-2031-6390, Peto, T. & Hodgson, R. (2024).
Anti–Vascular Endothelial Growth Factor Drugs Compared with Panretinal Photocoagulation for the Treatment of Proliferative Diabetic Retinopathy: A Cost-Effectiveness Analysis.
Value in Health, 27(7),
pp. 907-917.
doi: 10.1016/j.jval.2024.03.007